Parkinson'
Conditions
Interventions
bright light therapy will be administered for 12 weeks, during which time the dosage of the antiparkinsonian drug will remain unchanged.
Sponsors
National Hospital Organization Osaka Toneyama Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients themselves have agreed to participate in the exam, both in writing and by consent. 2. The age at the time of obtaining consent is 20 years or older and less than 85 years. 3.Patients with Parkinson's disease or Parkinson's syndrome with H & Y II or higher
Exclusion criteria
Exclusion criteria: 1) Patients with ophthalmic disease 2) Patients with drug addiction / alcoholism 3) Patients with severe physical symptoms other than Parkinson's disease (heart, liver, renal dysfunction, hematopoietic disorders, etc.) 4) Patients with severe mental symptoms (confusion, hallucinations, delusions, abnormal behavior, etc.) within 3 months before obtaining consent form 5) Other patients who are judged inappropriate by the attending physician to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Unified Parkinson Disease Rating Scale(4 weeks, 8 weeks, 12 weeks of treatment start) | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep evaluation scale(4 weeks, 8 weeks, 12 weeks of treatment start) | — |
Countries
Japan
Contacts
Public ContactTakuyuki Endo
National Hospital Organization Osaka Toneyama Medical Center Department of Neurology
Outcome results
None listed